Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
Open Access
- 1 August 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 10 (4), 1535-1541
- https://doi.org/10.1007/s13300-019-0654-y
Abstract
IntroductionHypoglycemia resulting from insulin therapy for treatment of diabetes increases the risk of adverse cardiovascular events. Determining biomarkers that provide accurate estimation of hypoglycemia risk may allow for more accurate patient management and care. The purpose of this study was to determine the cutoff value of serum albumin (s-alb) that increases the risk of hypoglycemia in patients treated with insulin degludec.MethodsThis study used a crossover design and randomized 30 patients admitted for glycemic control to compare differences between insulin glargine 300 U/ml (Gla300) and degludec treatments.ResultsThe cutoff value of s-alb associated with 24-h hypoglycemia and nocturnal hypoglycemia in patients treated with degludec was 3.8g/dl. In patients with s-alb levels<3.8g/dl, mean percentages of time with hypoglycemia, clinically important hypoglycemia, and nocturnal hypoglycemia were significantly lower in those treated with Gla300 compared with patients treated with degludec.ConclusionThis study identified a cutoff value for s-alb levels that indicates risk of hypoglycemia in patients treated with degludec. Monitoring s-alb levels in patients treated with degludec will help to mitigate the risk of hypoglycemia.Trial RegistrationUniversity Hospital Medical Information Network (UMIN 000031044).Keywords
This publication has 15 references indexed in Scilit:
- Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomesDiabetes, Obesity and Metabolism, 2016
- Clinical use of insulin degludecDiabetes Research and Clinical Practice, 2015
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)Diabetes Care, 2014
- Translating structure to clinical properties of an ideal basal insulin.2014
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal InsulinPharmaceutical Research, 2012
- Hypoglycemia and Cardiovascular RisksDiabetes Care, 2011
- Degludec insulin: A novel basal insulinIndian Journal of Endocrinology and Metabolism, 2011
- Insulin Detemir—A New Basal Insulin AnalogAnnals of Pharmacotherapy, 2005
- Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivoBiochemical Journal, 1995
- Glucose Counterregulation and Waning of Insulin in the Somogyi Phenomenon (Posthypoglycemic Hyperglycemia)New England Journal of Medicine, 1984